SG11202112158YA - Kcnt1 inhibitors and methods of use - Google Patents

Kcnt1 inhibitors and methods of use

Info

Publication number
SG11202112158YA
SG11202112158YA SG11202112158YA SG11202112158YA SG11202112158YA SG 11202112158Y A SG11202112158Y A SG 11202112158YA SG 11202112158Y A SG11202112158Y A SG 11202112158YA SG 11202112158Y A SG11202112158Y A SG 11202112158YA SG 11202112158Y A SG11202112158Y A SG 11202112158YA
Authority
SG
Singapore
Prior art keywords
kcnt1
inhibitors
methods
kcnt1 inhibitors
Prior art date
Application number
SG11202112158YA
Other languages
English (en)
Inventor
Botella Gabriel Martinez
Andrew Griffin
Paul Charifson
Kiran Reddy
Michael Kristopher Kahlig
Brian Marron
Original Assignee
Praxis Prec Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Prec Medicines Inc filed Critical Praxis Prec Medicines Inc
Publication of SG11202112158YA publication Critical patent/SG11202112158YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202112158YA 2019-05-03 2020-05-01 Kcnt1 inhibitors and methods of use SG11202112158YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962842849P 2019-05-03 2019-05-03
US202062982864P 2020-02-28 2020-02-28
PCT/US2020/031046 WO2020227101A1 (en) 2019-05-03 2020-05-01 Kcnt1 inhibitors and methods of use

Publications (1)

Publication Number Publication Date
SG11202112158YA true SG11202112158YA (en) 2021-12-30

Family

ID=73051241

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202112158YA SG11202112158YA (en) 2019-05-03 2020-05-01 Kcnt1 inhibitors and methods of use

Country Status (16)

Country Link
US (1) US20220259193A1 (zh)
EP (1) EP3962481A4 (zh)
JP (1) JP2022531388A (zh)
KR (1) KR20220016086A (zh)
CN (1) CN114269340A (zh)
AU (1) AU2020267356A1 (zh)
BR (1) BR112021022067A2 (zh)
CA (1) CA3139063A1 (zh)
CL (1) CL2021002877A1 (zh)
CO (1) CO2021016471A2 (zh)
EC (1) ECSP21087884A (zh)
IL (1) IL287768A (zh)
MX (1) MX2021013421A (zh)
PE (1) PE20220016A1 (zh)
SG (1) SG11202112158YA (zh)
WO (1) WO2020227101A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4210824A1 (en) * 2020-09-09 2023-07-19 University of Virginia Patent Foundation Inhibitors of spinster homolog 2 (spns2) for use in therapy
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
CN116194451A (zh) * 2020-11-27 2023-05-30 瑞石生物医药有限公司 芳基或杂芳基取代五元芳杂环化合物及其用途
EP4267133A2 (en) * 2020-12-22 2023-11-01 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2022231873A1 (en) * 2021-04-29 2022-11-03 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2022231872A1 (en) * 2021-04-29 2022-11-03 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2023211850A1 (en) * 2022-04-25 2023-11-02 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use
WO2023239839A1 (en) * 2022-06-08 2023-12-14 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
TW200301698A (en) * 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US20080021217A1 (en) * 2006-07-20 2008-01-24 Allen Borchardt Heterocyclic inhibitors of rho kinase
CA2903979A1 (en) * 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
JP6668329B2 (ja) * 2015-03-25 2020-03-18 国立研究開発法人国立長寿医療研究センター 新規オキサジアゾール誘導体及びこれを含有する医薬
WO2017170826A1 (ja) * 2016-03-30 2017-10-05 味の素株式会社 グルカゴン様ペプチド－１受容体作用増強活性を有する化合物
US11731966B2 (en) * 2017-04-04 2023-08-22 Praxis Precision Medicines, Inc. Compounds and their methods of use

Also Published As

Publication number Publication date
EP3962481A4 (en) 2023-03-22
CA3139063A1 (en) 2020-11-12
WO2020227101A1 (en) 2020-11-12
ECSP21087884A (es) 2022-01-31
KR20220016086A (ko) 2022-02-08
IL287768A (en) 2022-01-01
CN114269340A (zh) 2022-04-01
US20220259193A1 (en) 2022-08-18
EP3962481A1 (en) 2022-03-09
BR112021022067A2 (pt) 2022-05-17
PE20220016A1 (es) 2022-01-11
CO2021016471A2 (es) 2022-04-08
CL2021002877A1 (es) 2022-08-12
AU2020267356A1 (en) 2022-01-06
JP2022531388A (ja) 2022-07-06
MX2021013421A (es) 2022-02-11

Similar Documents

Publication Publication Date Title
IL287940A (en) fgfr inhibitors and methods of using them
IL279475A (en) Actonucleotidase inhibitors and methods of using them
IL287751A (en) kcnt1 inhibitors and methods of use
IL287768A (en) kcnt1 inhibitors and methods of use
IL283592A (en) Apol1 inhibitors and methods of using them
IL287973A (en) acss2 inhibitors and methods of their use
IL284640A (en) PCSK9 inhibitors and methods of using them
IL276711A (en) Arginase inhibitors and methods of using them
IL284661A (en) pcsk9 inhibitors and methods of using them
IL274504A (en) 2ACSS inhibitors and methods of their use
IL278989A (en) MASP-2 suppressors and methods of using them
EP3986894A4 (en) ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF
EP3846808A4 (en) PAPD5 INHIBITORS AND METHODS OF USE THEREOF
IL280924A (en) Arginase inhibitors and methods of using them
EP3959197A4 (en) PAPD5 INHIBITORS AND METHODS OF USE THEREOF
IL264854A (en) Spt5 inhibitors and methods of use thereof
IL286485A (en) pi4-kinase inhibitors and methods of using them
IL286149A (en) Caspase inhibitors and methods of using them
EP3793552C0 (en) ABHD12 INHIBITORS AND METHODS OF MANUFACTURE AND USE THEREOF
IL289127A (en) ppm1a inhibitors and methods of using them
IL285108A (en) Arginase inhibitors and methods of using them
EP3968994C0 (en) ABHD12 INHIBITORS AND METHODS FOR THE PRODUCTION AND USE THEREOF
EP4077332A4 (en) LIN28 INHIBITORS AND THEIR METHODS OF USE